Quality Of Life And Subgroup Analysis In A Phase 3 Randomized Study Of Ensartinib Vs Crizotinib In Alk-Positive Nsclc Patients: Exalt3.G. Selvaggi,Y. Wu,Z. Wang,G. Wu,E. Poddubskaya,M. Reck,T. Mok,A. Chiappori, D. H. Lee,V. Breder,S. Orlov,I. Cicin,Y. Cheng,Y. Liu,Y. Fan,J. Zhou,C. Liang,L. Mao,L. Horn,H. A. WakeleeJOURNAL OF THORACIC ONCOLOGY（2021）引用 1|浏览10暂无评分关键词ALK, NSCLC, ensartinibAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
